| COLLABORATIONS |
| 1 | The activity of the group consists mainly in coordinating the experiments performed by different CROs: Pharmasafe, Chiman, RTC (I), RCC (CH), Sequani, HLS, Inveresk, Quintiles (UK), CERB (FR), Notox (NL), BioTest, Quinta-Analytica (CZ), MDS |
|
| PUBLICATIONS |
| 1 |
Losi G, Lanza M, Makovec F, Artusi R, Caselli
G, Puia G (2005) Functional in vitro characterization of CR 3394:
A novel voltage dependent N-methyl-d-aspartate (NMDA) receptor antagonist.
Neuropharmacology. Oct 14; [Epub ahead of print]. |
| 2 |
Ferrari F, Mennuni L, Caselli GF, Zanelli T,
Makovec F (2004) Pharmacological profile of CR3465, a new leukotriene
CysLT1 receptor antagonist with broad anti-inflammatory activityEur
J Pharmacol 504: 223- 233. |
| 3 |
Bossu` P, Neumann D, Del Giudice E, Ciaramella
A, Gloaguen I, Fantuzzi G, Dinarello CA, Di Carlo E, Musiani P,
Meroni PL, Caselli GF, Ruggiero P, Boraschi D (2003). IL-18 cDNA
vaccination protects mice from spontaneous lupus-like autoimmune
disease. PNAS 100(24):14181-14186. |
| 4 |
Michieli P,Cavassa S, Basilico C, De Luca A,
Mazzone M, Asti C, Chiusaroli R, Guglielmi M, Bossù P, Colotta
F, Caselli G, Comoglio PM (2002). An Hgf-Msp chimaera disassociates
the trophic properties of scatter factors from their pro-invasive
activity. Nature. Biotechnology 20:488-95. |
| 5 |
Pagliei S, Ghezzi P, Bizzarri C, Sabbatini
V, Frascaroli G, Sozzani S, Caselli G, Bertini R (2002). Thioredoxin
specifically cross-desensitizes monocytes to MCP-1 Eur Cytokine
Netw 13(2):261-7. |
| 6 |
Ceschel GC, Maffei P, Porzio S, Melillo G,
Caselli GF, Dragani MC, Gentile MM, Clavenna G. (2002). In vitro
permeation screening of a new formulation of thiocolchicoside containing
various enhancers. drug deliv 9(4):259-63. |
| 7 |
Brandolini L, Intilangelo A, Caselli G, Bertini
R (2001). Role of tumor necrosis factor-alpha in endotoxin-induced
lung parenchymal hyporesponsiveness in mice. Biochem Pharmacol 62:1141-4. |
|